TY - JOUR
T1 - Chemotherapy Foundation Symposium XXVI
T2 - Innovative cancer therapy for tomorrow - Epigenetic therapies for myelodysplastic syndromes and leukemia: Azacytidine (Vidaza) and decitabine (Dacogen)
AU - Goldenberg, Marvin M.
AU - Kantarjian, Hagop M.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/12
Y1 - 2008/12
N2 - Hypomethylating agents (decitabine and AZA) might play a role in AML treatment, especially in elderly patients as well as in those receiving maintenance therapy after a complete response. An ongoing study is comparing decitabine with best standard therapy (supportive treatment with low-dose cytarabine) in older patients. Current studies include decitabine combinations with histone deacetylase inhibitors (valproic acid, vorinostat).
AB - Hypomethylating agents (decitabine and AZA) might play a role in AML treatment, especially in elderly patients as well as in those receiving maintenance therapy after a complete response. An ongoing study is comparing decitabine with best standard therapy (supportive treatment with low-dose cytarabine) in older patients. Current studies include decitabine combinations with histone deacetylase inhibitors (valproic acid, vorinostat).
UR - http://www.scopus.com/inward/record.url?scp=58449099017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58449099017&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:58449099017
SN - 1052-1372
VL - 33
SP - 713
JO - P and T
JF - P and T
IS - 12
ER -